Effect of high doses of 2-CdA on Schwann cells of mouse peripheral nerve

Journal of Submicroscopic Cytology and Pathology

Volumn 28, Issue 3, 1996, Pages 319-323

  Djaldetti, R ^a   Hart, J ^a   Alexandrova, S ^a   Cohen, S ^a,b   Beilin, B ^a,b   Djaldetti, M ^a   Bessler, H ^a  

^a HASHARON HOSPITAL   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

2 CdA; Peripheral nerve; Schwann cells

Indexed keywords

ANTIMETABOLITE; CLADRIBINE;

ANIMAL; ARTICLE; C57BL MOUSE; COMPARATIVE STUDY; CYTOLOGY; DRUG EFFECT; ELECTRON MICROSCOPY; MOUSE; MYELIN SHEATH; MYELINATED NERVE; NERVE FIBER; PERIPHERAL NERVE; SCHWANN CELL; SCIATIC NERVE; ULTRASTRUCTURE;

ANIMALS; ANTIMETABOLITES; AXONS; CLADRIBINE; MICE; MICE, INBRED C57BL; MICROSCOPY, ELECTRON; MYELIN SHEATH; NERVE FIBERS; NERVE FIBERS, MYELINATED; PERIPHERAL NERVES; SCHWANN CELLS; SCIATIC NERVE;

EID: 0030192387     PISSN: 11229497     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. BEUTLER E., 1992. Cladribine (2-chlorodeoxyadenosine). Lancet, 340, 952-956.
2. BRYSON H.M. and SORKIN E.M., 1993. Cladribine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in haematological malignancies. Drugs, 46, 872-894.
3. CAVALETTI G., BOGLIUN G., MARZORATI L., ZINCONE A., MARZOLA M., COLOMBO N. and TREDICI G., 1995. Peripheral neurotoxicity of taxol in patients previously treated with cisplatin. Cancer, 75, 1141-1150.
4. CHAULDRY V., ROWINSKY E.K., SARTORIUS S.E., DONEHOWER R.C. and CORNBLATH D.R., 1994. Peripheral neuropathy from taxol and cisplatin combination chemotherapy: Clinical and electrophysiological studies. Ann. Neurol., 35, 304-311.
5. CHESON B.D., VENA D.A., FOSS A.M. and SORENSEN J.M., 1994. Neurotoxicity of purine analogs: A review. J. Clin. Oncol., 12, 2216-2228.
6. GOTTSCHALK P.G. and DYCK P.J., 1968. Vinca alkaloid neuropathy: Nerve biopsy studies in rats and in man. Neurology, 18, 875-882.
7. HOLLAND J.F., SCHARLAU C., GAILANI S., KRANT M.J., OLSON K.B., HORTON J., SCHNIDER B.I., LYNCH J.J., OWENS A., CARBONE P.P., COLSKY J., GROB D., MILLER S.P. and HALL T.C., 1973. Vincristine treatment of advanced cancer: A cooperative study of 392 cases. Cancer Res., 33, 1258-1264.
8. KORNBLAU S.M., CORTES-FRANCO J. and ESTAY E., 1993. Neurotoxicity associated with fludarabine and cytosine arabinoside chemotherapy for acute leukemia and myelodysplasia. Leukemia, 7, 378-383.
9. MCLEOD J.G. and PENNY R., 1969. Vincristine neuropathy: An electrophysiological and histological study. J. Neurosurg. Psychiatry, 32, 297-304.
10. MERKEL D.E., GRIFFIN N.L., KAGAN-HALLET K. and VON HOFF D.D., 1986. Central nervous system toxicity with fludarabine. Cancer Treat. Rep., 70, 1449-1450.
11. SANDLER S.G., TOBIN W. and HENDERSON E.S., 1969. Vincristine-induced neuropathy. Neurology, 19, 367-374.
12. SAVEN A., KAWASAKI H., CARRERA C.J., WALTZ T., COPELAND B., ZYROFF J., KOSTY M., CARSON D.A., BEUTLER E. and PIRO L.D., 1993. 2-chlorodeoxyadenosine dose escalation in nonhematologic malignancies. J. Clin. Oncol., 11, 671-678.